Last reviewed · How we verify
Oral Cholera Vaccine (OCV)
The Oral Cholera Vaccine (OCV) works by stimulating the body's immune system to produce antibodies against Vibrio cholerae, the bacteria that causes cholera.
The Oral Cholera Vaccine (OCV) works by stimulating the body's immune system to produce antibodies against Vibrio cholerae, the bacteria that causes cholera. Used for Prevention of cholera in individuals traveling to or living in areas where cholera is common.
At a glance
| Generic name | Oral Cholera Vaccine (OCV) |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the administration of inactivated Vibrio cholerae bacteria, which triggers an immune response without causing the disease. The immune system then produces antibodies that can recognize and neutralize the bacteria, providing protection against cholera.
Approved indications
- Prevention of cholera in individuals traveling to or living in areas where cholera is common
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- Vaccine- and Infection-derived Correlates of Protection for Cholera. (NA)
- Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus (PHASE3)
- Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi (NA)
- Co-administration Study of OCV, TCV and MR (PHASE3)
- Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ (PHASE3)
- Immune Response to a Delayed Second Dose of Oral Cholera Vaccine (PHASE4)
- First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: